Novel Use of Tamoxifen to Reduce Recurrent Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices

• DOI: 10.1007/s12265-020-10084-7
• Publication Date: 2020-11-11T16:02:37Z
• Authors: Michael E. Plazak; Stephen J. Hankinson; Erik N. Sorensen; Brent N. Reed; Bharath Ravichandran; Van-Khue Ton
• Keywords: Adult; Male; Time Factors; Middle Aged; Hemostatics; 3. Good health; Prosthesis Implantation; Tamoxifen; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Recurrence; Secondary Prevention; Humans; Female; Heart-Assist Devices; Erythrocyte Transfusion; Gastrointestinal Hemorrhage; Retrospective Studies

Gastrointestinal bleeding (GIB) is a frequent complication in patients with continuous-flow left ventricular assist devices (LVAD). We retrospectively evaluated eight patients implanted with a HeartWare LVAD between July 2017 and June 2020 who experienced at least one episode of GIB and were started on tamoxifen 20 mg once daily for secondary prevention. Tamoxifen was associated with a significant decrease in major GIB from a median of 3 (IQR 1.4-7) events/patient-year pre-tamoxifen initiation to 0 (IQR 0-0.9) events/patient-year post-tamoxifen initiation (p = 0.02). Transfusion of packed red blood cells also decreased from 16.8 (IQR 9.9-30.6) units/patient-year pre-tamoxifen initiation to 1.5 (IQR 0-7.5) units/patient-year post-tamoxifen (p = 0.04). Tamoxifen was well tolerated and no thromboembolic complications were observed. This small cohort study suggests that tamoxifen is associated with reduced GIB and transfusion requirements, with no apparent increase in thrombotic risk. A larger, randomized study is warranted to confirm the results of this exploratory analysis. Graphical abstract.